Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

National Trends in Active Surveillance for Prostate Cancer: Validation of Medicare Claims-based Algorithms.

Modi PK, Kaufman SR, Qi J, Lane BR, Cher ML, Miller DC, Hollenbeck BK, Shahinian VB, Dupree JM.

Urology. 2018 Jul 7. pii: S0090-4295(18)30628-9. doi: 10.1016/j.urology.2018.06.037. [Epub ahead of print]

PMID:
29990573
2.

Observation versus treatment among men with favorable risk prostate cancer in a community-based integrated health care system: a retrospective cohort study.

Kariburyo F, Wang Y, Cheng IE, Wang L, Morgenstern D, Xie L, Meadows E, Danella J, Cher ML.

BMC Urol. 2018 Jun 4;18(1):55. doi: 10.1186/s12894-018-0372-1.

3.

Association Between Early Confirmatory Testing and the Adoption of Active Surveillance for Men With Favorable-risk Prostate Cancer.

Kaye DR, Qi J, Morgan TM, Linsell S, Lane BR, Montie JE, Cher ML, Miller DC; Michigan Urological Surgery Improvement Collaborative.

Urology. 2018 Aug;118:127-133. doi: 10.1016/j.urology.2018.04.038. Epub 2018 May 21.

PMID:
29792972
4.

Avoidance of androgen deprivation therapy in radiorecurrent prostate cancer as a clinically meaningful endpoint for salvage cryoablation.

Ginsburg KB, Elshafei A, Yu C, Jones JS, Cher ML.

Prostate. 2017 Oct;77(14):1446-1450. doi: 10.1002/pros.23406. Epub 2017 Aug 29.

PMID:
28856702
5.

A Roadmap for Improving the Management of Favorable Risk Prostate Cancer.

Auffenberg GB, Lane BR, Linsell S, Brachulis A, Ye Z, Rakic N, Montie J, Miller DC, Cher ML.

J Urol. 2017 Dec;198(6):1220-1222. doi: 10.1016/j.juro.2017.07.085. Epub 2017 Aug 3. No abstract available.

PMID:
28782516
6.

Establishment of a Web-based System for Collection of Patient-reported Outcomes After Radical Prostatectomy in a Statewide Quality Improvement Collaborative.

Lucas SM, Kim TK, Ghani KR, Miller DC, Linsell S, Starr J, Peabody JO, Hurley P, Montie J, Cher ML; Michigan Urological Surgery Improvement Collaborative.

Urology. 2017 Sep;107:96-102. doi: 10.1016/j.urology.2017.04.058. Epub 2017 Jun 23.

PMID:
28652160
7.

Practice- vs Physician-Level Variation in Use of Active Surveillance for Men With Low-Risk Prostate Cancer: Implications for Collaborative Quality Improvement.

Auffenberg GB, Lane BR, Linsell S, Cher ML, Miller DC.

JAMA Surg. 2017 Oct 1;152(10):978-980. doi: 10.1001/jamasurg.2017.1586. No abstract available.

8.

Infection-Related Hospital Admissions After Prostate Biopsy in United States Men.

Evans R, Loeb A, Kaye KS, Cher ML, Martin ET.

Open Forum Infect Dis. 2017 Jan 13;4(1):ofw265. doi: 10.1093/ofid/ofw265. eCollection 2017 Winter.

9.

Prospective assessment of positioning-related pain in robotic urologic surgery.

Ginsburg KB, Pape K, Heilbronn C, Levin M, Cher ML.

J Robot Surg. 2018 Mar;12(1):97-101. doi: 10.1007/s11701-017-0701-5. Epub 2017 May 3.

PMID:
28470407
10.

Prostate cancer family history and eligibility for active surveillance: a systematic review of the literature.

Telang JM, Lane BR, Cher ML, Miller DC, Dupree JM.

BJU Int. 2017 Oct;120(4):464-467. doi: 10.1111/bju.13862. Epub 2017 May 3. Review.

PMID:
28371016
11.

Calculating life expectancy to inform prostate cancer screening and treatment decisions.

Hawken SR, Auffenberg GB, Miller DC, Lane BR, Cher ML, Abdollah F, Cho H, Ghani KR; Michigan Urological Surgery Improvement Collaborative.

BJU Int. 2017 Jul;120(1):9-11. doi: 10.1111/bju.13812. Epub 2017 Mar 10. No abstract available.

12.

Pharmacological targeting of CXCL12/CXCR4 signaling in prostate cancer bone metastasis.

Conley-LaComb MK, Semaan L, Singareddy R, Li Y, Heath EI, Kim S, Cher ML, Chinni SR.

Mol Cancer. 2016 Nov 3;15(1):68.

13.

Appropriateness Criteria for Active Surveillance of Prostate Cancer.

Cher ML, Dhir A, Auffenberg GB, Linsell S, Gao Y, Rosenberg B, Jafri SM, Klotz L, Miller DC, Ghani KR, Bernstein SJ, Montie JE, Lane BR; Michigan Urological Surgery Improvement Collaborative.

J Urol. 2017 Jan;197(1):67-74. doi: 10.1016/j.juro.2016.07.005. Epub 2016 Jul 14.

PMID:
27422298
14.

Gene expression analysis of bone metastasis and circulating tumor cells from metastatic castrate-resistant prostate cancer patients.

Cho WJ, Oliveira DS, Najy AJ, Mainetti LE, Aoun HD, Cher ML, Heath E, Kim HR, Bonfil RD.

J Transl Med. 2016 Mar 15;14:72. doi: 10.1186/s12967-016-0829-5.

15.

Variation in the use of postoperative radiotherapy among high-risk patients following radical prostatectomy.

Morgan TM, Hawken SR, Ghani KR, Miller DC, Feng FY, Linsell SM, Salisz JA, Gao Y, Montie JE, Cher ML.

Prostate Cancer Prostatic Dis. 2016 Jun;19(2):216-21. doi: 10.1038/pcan.2016.9. Epub 2016 Mar 8.

PMID:
26951715
16.

Primary Cryotherapy for High-Grade Clinically Localized Prostate Cancer: Oncologic and Functional Outcomes from the COLD Registry.

Tay KJ, Polascik TJ, Elshafei A, Cher ML, Given RW, Mouraviev V, Ross AE, Jones JS.

J Endourol. 2016 Jan;30(1):43-8. doi: 10.1089/end.2015.0403. Epub 2015 Oct 20.

PMID:
26414656
17.

ERG/AKR1C3/AR Constitutes a Feed-Forward Loop for AR Signaling in Prostate Cancer Cells.

Powell K, Semaan L, Conley-LaComb MK, Asangani I, Wu YM, Ginsburg KB, Williams J, Squire JA, Maddipati KR, Cher ML, Chinni SR.

Clin Cancer Res. 2015 Jun 1;21(11):2569-79. doi: 10.1158/1078-0432.CCR-14-2352. Epub 2015 Mar 9.

18.

MUSIC: patterns of care in the radiographic staging of men with newly diagnosed low risk prostate cancer.

Ross I, Womble P, Ye J, Linsell S, Montie JE, Miller DC, Cher ML.

J Urol. 2015 Apr;193(4):1159-62. doi: 10.1016/j.juro.2014.10.102. Epub 2014 Oct 31.

PMID:
25444985
19.

Cryotherapy with concurrent CpG oligonucleotide treatment controls local tumor recurrence and modulates HER2/neu immunity.

Veenstra JJ, Gibson HM, Littrup PJ, Reyes JD, Cher ML, Takashima A, Wei WZ.

Cancer Res. 2014 Oct 1;74(19):5409-20. doi: 10.1158/0008-5472.CAN-14-0501. Epub 2014 Aug 4.

20.

Bone-induced c-kit expression in prostate cancer: a driver of intraosseous tumor growth.

Mainetti LE, Zhe X, Diedrich J, Saliganan AD, Cho WJ, Cher ML, Heath E, Fridman R, Kim HR, Bonfil RD.

Int J Cancer. 2015 Jan 1;136(1):11-20. doi: 10.1002/ijc.28948. Epub 2014 May 20.

21.

Transcriptional regulation of CXCR4 in prostate cancer: significance of TMPRSS2-ERG fusions.

Singareddy R, Semaan L, Conley-Lacomb MK, St John J, Powell K, Iyer M, Smith D, Heilbrun LK, Shi D, Sakr W, Cher ML, Chinni SR.

Mol Cancer Res. 2013 Nov;11(11):1349-61. doi: 10.1158/1541-7786.MCR-12-0705. Epub 2013 Aug 5.

22.

PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling.

Conley-LaComb MK, Saliganan A, Kandagatla P, Chen YQ, Cher ML, Chinni SR.

Mol Cancer. 2013 Jul 31;12(1):85. doi: 10.1186/1476-4598-12-85.

23.

Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM.

Kong D, Heath E, Chen W, Cher ML, Powell I, Heilbrun L, Li Y, Ali S, Sethi S, Hassan O, Hwang C, Gupta N, Chitale D, Sakr WA, Menon M, Sarkar FH.

PLoS One. 2012;7(3):e33729. doi: 10.1371/journal.pone.0033729. Epub 2012 Mar 19.

24.

Cediranib inhibits both the intraosseous growth of PDGF D-positive prostate cancer cells and the associated bone reaction.

Najy AJ, Jung YS, Won JJ, Conley-LaComb MK, Saliganan A, Kim CJ, Heath E, Cher ML, Bonfil RD, Kim HR.

Prostate. 2012 Sep 1;72(12):1328-38. doi: 10.1002/pros.22481. Epub 2011 Dec 27.

25.

PTEN regulates PDGF ligand switch for β-PDGFR signaling in prostate cancer.

Conley-LaComb MK, Huang W, Wang S, Shi D, Jung YS, Najy A, Fridman R, Bonfil RD, Cher ML, Chen YQ, Kim HR.

Am J Pathol. 2012 Mar;180(3):1017-27. doi: 10.1016/j.ajpath.2011.11.021. Epub 2011 Dec 28.

26.

A novel function for platelet-derived growth factor D: induction of osteoclastic differentiation for intraosseous tumor growth.

Huang W, Fridman Y, Bonfil RD, Ustach CV, Conley-LaComb MK, Wiesner C, Saliganan A, Cher ML, Kim HR.

Oncogene. 2012 Oct 18;31(42):4527-35. doi: 10.1038/onc.2011.573. Epub 2011 Dec 12.

27.

Circulating tumor cells: finding the needle in the haystack.

Zhe X, Cher ML, Bonfil RD.

Am J Cancer Res. 2011;1(6):740-51. Epub 2011 Jun 1.

28.

Primary full-gland prostate cryoablation in older men (> age of 75 years): results from 860 patients tracked with the COLD Registry.

Dhar N, Ward JF, Cher ML, Jones JS.

BJU Int. 2011 Aug;108(4):508-12. doi: 10.1111/j.1464-410X.2011.10238.x. Epub 2011 Jul 1.

29.

Soy isoflavones in conjunction with radiation therapy in patients with prostate cancer.

Ahmad IU, Forman JD, Sarkar FH, Hillman GG, Heath E, Vaishampayan U, Cher ML, Andic F, Rossi PJ, Kucuk O.

Nutr Cancer. 2010;62(7):996-1000. doi: 10.1080/01635581.2010.509839.

30.

Androgens Induce Functional CXCR4 through ERG Factor Expression in TMPRSS2-ERG Fusion-Positive Prostate Cancer Cells.

Cai J, Kandagatla P, Singareddy R, Kropinski A, Sheng S, Cher ML, Chinni SR.

Transl Oncol. 2010 Jun 1;3(3):195-203.

31.

Shedding of RANKL by tumor-associated MT1-MMP activates Src-dependent prostate cancer cell migration.

Sabbota AL, Kim HR, Zhe X, Fridman R, Bonfil RD, Cher ML.

Cancer Res. 2010 Jul 1;70(13):5558-66. doi: 10.1158/0008-5472.CAN-09-4416. Epub 2010 Jun 15.

32.

Phase II trial of capecitabine and weekly docetaxel for metastatic castrate resistant prostate cancer.

Vaishampayan UN, Marur S, Heilbrun LK, Cher ML, Dickow B, Smith DW, Al Hasan SA, Eliason J.

J Urol. 2009 Jul;182(1):317-23. doi: 10.1016/j.juro.2009.02.105. Epub 2009 May 17.

33.

Are matrix metalloproteinases relevant therapeutic targets for prostate cancer bone metastasis?

Bonfil RD, Fridman R, Mobashery S, Cher ML.

Curr Oncol. 2008 Aug;15(4):188-92. No abstract available.

34.

C-kit and its ligand stem cell factor: potential contribution to prostate cancer bone metastasis.

Wiesner C, Nabha SM, Dos Santos EB, Yamamoto H, Meng H, Melchior SW, Bittinger F, Thüroff JW, Vessella RL, Cher ML, Bonfil RD.

Neoplasia. 2008 Sep;10(9):996-1003.

35.

Prostate cancer cell-derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnover.

Dong Z, Saliganan AD, Meng H, Nabha SM, Sabbota AL, Sheng S, Bonfil RD, Cher ML.

Neoplasia. 2008 May;10(5):439-49.

36.

Platelet-derived growth factor-D overexpression contributes to epithelial-mesenchymal transition of PC3 prostate cancer cells.

Kong D, Wang Z, Sarkar SH, Li Y, Banerjee S, Saliganan A, Kim HR, Cher ML, Sarkar FH.

Stem Cells. 2008 Jun;26(6):1425-35. doi: 10.1634/stemcells.2007-1076. Epub 2008 Apr 10.

37.

CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone.

Chinni SR, Yamamoto H, Dong Z, Sabbota A, Bonfil RD, Cher ML.

Mol Cancer Res. 2008 Mar;6(3):446-57. doi: 10.1158/1541-7786.MCR-07-0117.

38.

Bone marrow stromal cells enhance prostate cancer cell invasion through type I collagen in an MMP-12 dependent manner.

Nabha SM, dos Santos EB, Yamamoto HA, Belizi A, Dong Z, Meng H, Saliganan A, Sabbota A, Bonfil RD, Cher ML.

Int J Cancer. 2008 Jun 1;122(11):2482-90. doi: 10.1002/ijc.23431.

39.

Lycopene and soy isoflavones in the treatment of prostate cancer.

Vaishampayan U, Hussain M, Banerjee M, Seren S, Sarkar FH, Fontana J, Forman JD, Cher ML, Powell I, Pontes JE, Kucuk O.

Nutr Cancer. 2007;59(1):1-7.

PMID:
17927495
40.

Proteases, growth factors, chemokines, and the microenvironment in prostate cancer bone metastasis.

Bonfil RD, Chinni S, Fridman R, Kim HR, Cher ML.

Urol Oncol. 2007 Sep-Oct;25(5):407-11. Review.

PMID:
17826661
41.

Prostate cancer-associated membrane type 1-matrix metalloproteinase: a pivotal role in bone response and intraosseous tumor growth.

Bonfil RD, Dong Z, Trindade Filho JC, Sabbota A, Osenkowski P, Nabha S, Yamamoto H, Chinni SR, Zhao H, Mobashery S, Vessella RL, Fridman R, Cher ML.

Am J Pathol. 2007 Jun;170(6):2100-11.

42.

Heterogeneous activation of MMP-9 due to prostate cancer-bone interaction.

Wiesner C, Bonfil RD, Dong Z, Yamamoto H, Nabha SM, Meng H, Saliganan A, Sabbota A, Cher ML.

Urology. 2007 Apr;69(4):795-9.

PMID:
17445684
43.

Host matrix metalloproteinase-9 contributes to tumor vascularization without affecting tumor growth in a model of prostate cancer bone metastasis.

Nabha SM, Bonfil RD, Yamamoto HA, Belizi A, Wiesner C, Dong Z, Cher ML.

Clin Exp Metastasis. 2006;23(7-8):335-44. Epub 2006 Nov 30.

PMID:
17136575
44.

Quantitative assessment of small intraosseous prostate cancer burden in SCID mice using fluorescence imaging.

Yamamoto H, Bonfil RD, Wiesner C, Nabha S, Dong Z, Meng H, Saliganan A, Sabbota A, Chinni SR, Cher ML.

Prostate. 2007 Jan 1;67(1):107-14.

PMID:
17075820
45.

Cancer interaction with the bone microenvironment: a workshop of the National Institutes of Health Tumor Microenvironment Study Section.

Cher ML, Towler DA, Rafii S, Rowley D, Donahue HJ, Keller E, Herlyn M, Cho EA, Chung LW.

Am J Pathol. 2006 May;168(5):1405-12. No abstract available.

47.

Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system.

Yin S, Lockett J, Meng Y, Biliran H Jr, Blouse GE, Li X, Reddy N, Zhao Z, Lin X, Anagli J, Cher ML, Sheng S.

Cancer Res. 2006 Apr 15;66(8):4173-81.

48.

Inhibition of human prostate cancer growth, osteolysis and angiogenesis in a bone metastasis model by a novel mechanism-based selective gelatinase inhibitor.

Bonfil RD, Sabbota A, Nabha S, Bernardo MM, Dong Z, Meng H, Yamamoto H, Chinni SR, Lim IT, Chang M, Filetti LC, Mobashery S, Cher ML, Fridman R.

Int J Cancer. 2006 Jun 1;118(11):2721-6.

49.

CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12.

Chinni SR, Sivalogan S, Dong Z, Filho JC, Deng X, Bonfil RD, Cher ML.

Prostate. 2006 Jan 1;66(1):32-48.

PMID:
16114056
50.

High frequency of allelic losses in high-grade prostate cancer is associated with biochemical progression after radical prostatectomy.

Valeri A, Fromont G, Sakr W, Azzouzi R, Dey J, Chantrel-Groussard K, Latil A, Berthon P, Cussenot O, Pontes JE, Cher ML.

Urol Oncol. 2005 Mar-Apr;23(2):87-92.

PMID:
15869992

Supplemental Content

Support Center